Evidence map›Paper›PMID 30824296›Full record

Trial reportEuropean urology2019

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Jonas Hugosson, Monique J Roobol, Marianne Månsson, Teuvo L J Tammela, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Sigrid V Carlsson, Kirsi M Talala and 22 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 349 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
349citing papers in PubMed, 8 pooled it
49.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05443412 recruitingnot on this mapstarted 2023, after this paper: background citation

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection: A Synergy of Novel Biomarkers, Advanced Imaging, and Robotic-assisted Diagnosis

TypeobservationalSponsorChinese University of Hong KongRan2023 to 2026Enrolled510ConditionsProstate CancerArmsDiagnostic test for prostate cancer
NCT05603351 naunknown statusnot on this mapstarted 2022, after this paper: background citation

ProstaPilot: Prostate Cancer Screening Using MRI With an Abbreviated Protocol

TypeinterventionalSponsorMasaryk Memorial Cancer InstituteRan2022 to 2025Enrolled300ConditionsProstate CancerArmsmagnetic resonance, serum PSA examination, Biopsy
3 · Its place in the literature

Who cites it

349 citing papers in PubMed, 8 syntheses or guidelines pooled it, 676 citations in OpenAlex.

  1. Prostate-specific antigen (PSA) test for prostate cancer screening.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. [Current status of prostate cancer screening research].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Review

289 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 16 institutions in 11 countries.

Jonas HugossonDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden. Electronic address: jonas.hugosson@gu.se.
Monique J RoobolErasmus Medical Centre, Rotterdam, The Netherlands.
Marianne MånssonDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden.
Teuvo L J TammelaUniversity of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland.
Marco ZappaISPRO, Oncological network, Prevention, and Research Institute, Florence, Italy.
Vera NelenProvinciaal Instituut voor Hygiëne, Antwerp, Belgium.
Maciej KwiatkowskiDepartment of Urology, Cantonal Hospital Aarau, Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany.
Marcos LujanUrology Department, Hospital Infanta Cristina, Parla, Madrid, Spain.
Sigrid V CarlssonDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden; Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kirsi M TalalaFinnish Cancer Registry, Helsinki, Finland.
Hans LiljaDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
Louis J DenisEuropa Uomo, Oncology Centre Antwerp, Antwerp, Belgium.
Franz ReckerDepartment of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
Alvaro PaezDepartment of Urology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Donella PulitiISPRO, Oncological network, Prevention, and Research Institute, Florence, Italy.
Arnauld VillersDepartment of Urology, CHU Lille, University Lille Nord de France, Lille, France.
Xavier RebillardUrology Department, Clinique Beau Soleil, Montpellier, France.
Tuomas P KilpeläinenDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ulf H StenmanDepartment of Pathology, Fimlab Laboratories, Tampere, Finland.
Rebecka Arnsrud GodtmanDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden.
Karin Stinesen KollbergDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden.
Sue M MossCentre for Cancer Prevention, Wolfson Institute of Preventative Medicine, Queen Mary University of London, Charterhouse Square, UK.
Paula KujalaDepartment of Pathology, Fimlab Laboratories, Tampere, Finland.
Kimmo TaariDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Andreas HuberDepartment of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland.
Theodorus van der KwastLaboratory Medicine Program, University Health Network, Toronto, Canada.
Eveline A HeijnsdijkErasmus Medical Centre, Department of Public Health, Rotterdam, The Netherlands.
Chris BangmaErasmus Medical Centre, Rotterdam, The Netherlands.
Harry J De KoningErasmus Medical Centre, Department of Public Health, Rotterdam, The Netherlands.
Fritz H SchröderErasmus Medical Centre, Rotterdam, The Netherlands.
Anssi AuvinenProstate Cancer Research Center, Faculty of Social Sciences, University of Tampere, Tampere, Finland.
ERSPC investigators
Erasmus University Rotterdam · NLUniversity of Gothenburg · SEKantonsspital Aarau · CHFimlab (Finland) · FITampere University · FIUniversity of Helsinki · FIClinique du Millénaire · FRFinnish Cancer Registry · FIHospital Universitario de Fuenlabrada · ESHospital Universitario Infanta Cristina · ESLund University · SEMemorial Sloan Kettering Cancer Center · USProvincial Institute for Hygiene · BEQueen Mary University of London · GBUniversité Lille Nord de France · FRUniversity Health Network · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundThe European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality.

objectiveTo determine whether PSA screening decreases PCa mortality for up to 16yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended. DESIGN, SETTING, AND

participantsThis multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182160 men, followed up until 2014 (maximum of 16yr), with a predefined core age group of 162389 men (55-69yr), selected from population registry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome was PCa mortality, also assessed with adjustment for nonparticipation and the number of screening rounds attended. RESULTS AND LIMITATIONS: The rate ratio of PCa mortality was 0.80 (95% confidence interval [CI] 0.72-0.89, p<0.001) at 16yr. The difference in absolute PCa mortality increased from 0.14% at 13yr to 0.18% at 16yr. The number of men needed to be invited for screening to prevent one PCa death was 570 at 16yr compared with 742 at 13yr. The number needed to diagnose was reduced to 18 from 26 at 13yr. Men with PCa detected during the first round had a higher prevalence of PSA >20ng/ml (9.9% compared with 4.1% in the second round, p<0.001) and higher PCa mortality (hazard ratio=1.86, p<0.001) than those detected subsequently.

conclusionsFindings corroborate earlier results that PSA screening significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level. PATIENT SUMMARY: In this report, we looked at the outcomes from prostate cancer in a large European population. We found that repeated screening reduces the risk of dying from prostate cancer.

Indexed as

AgedEarly Detection of CancerEuropeFollow-Up StudiesHumansIncidenceMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsTime FactorsProstate-Specific AntigenMortalityProstate cancerProstate-specific antigenScreening

Identifiers

PMID30824296
PMCPMC7513694
OpenAlexW2916798133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.